Apyx Medical Corporation Announces Launch of Renuvion® in China

Core Insights - Apyx Medical Corporation has launched Renuvion in China, marking a significant step in its global expansion strategy [2][3] - The company has entered into a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd., to facilitate the sales and marketing of Renuvion in the Chinese market [1][2] - Initial market clearance has been received from the National Medical Products Administration of China, indicating regulatory approval for the product [1] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion and J-Plasma, which provide controlled heat to tissue for surgical applications [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents, showcasing the company's commitment to clinical validation [3] Partner Overview - BeauCare Clinics Investment Co., Ltd. (BCC) is a leading player in China's medical aesthetics industry, operating over 60 medical aesthetics hospitals and clinics across 15 cities [4] - BCC has established a strong supply chain and a group purchasing alliance with over 400 members, enhancing its market position in the medical aesthetics sector [4]